Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Regulatory Briefs: Microbiology Panel Meeting; Advisory Committee Nomination Portal

This article was originally published in The Gray Sheet

Executive Summary

FDA’s Microbiology Devices Panel advisory committee will vote on Roche’s cobas HPV Test as a first-line screening test. The agency launched an advisory committee nomination portal and sought nominations for certain device advisory panels. More regulatory news.

You may also be interested in...

Regulatory Briefs: FDA Device Reclassifications, Meetings Announcements

FDA proposes class II for nonthermal shortwave therapy devices and updates regulations to reflect class II designation for neuropsychiatric assessment device. Meetings on manufacturing quality, clinical trials and medical countermeasures announced. More regulatory news.

Regulatory Briefs: MAUDE Replacement; Electronic Source Data Guidance; Social Media Monitoring

The device center plans to replace the MAUDE adverse events database system by the end of the year. Agency issues final guidance on electronic source data in clinical investigations. FDA purchases social media monitoring software to gauge the effectiveness of its online communications. More regulatory news.

Regulatory News In Brief

Lawmakers urge OMB to release unique device identifier rule. FDA selects device firms for early feasibility study pilot. More regulatory briefs.


Related Companies

Latest News
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts